- Home
- » Tags
- » Fast track (FDA)
Top View
- October 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Fast Track Designation: How Aleon Can Help Sponsors Speed up Their Drug Development to Serve the Underserved
- Alternative Drug Approval Pathways
- Claims and Billing Tool
- Wednesday December 16, 2015 4:30Pm
- (Olaratumab Injection, 10 Mg/Ml), in • EMD Serono Inc
- COVID-19: Legal Considerations for Bringing a New Vaccine to Market
- Final Bill Report E2shb 1224
- Immutep Achieves Fast Track Designation for Efti from US FDA
- Off-Label Prescription Advertising, the Fda and the First Amendment: a Study in the Values of Commercial Speech Protection
- European Approval Process Coverage Winners & Losers: a Deep-Dive Into the EMA’S PRIME Scheme
- FDA Expedited Programs with a Focus on Breakthrough Therapy
- FDA Approvals and Expedited Pathways Used — New Molecular Entities
- Modernizing Expedited Development Programs FRIENDS of CANCER RESEARCH ANNUAL MEETING 2020
- CY 2020 Fast Track Calendar Year Approvals* Data As of 31-Dec-2020 Total of 37 Approvals
- Introduction to the FDA Drug Approval Process and Off Label Use
- Oncosec Granted FDA Fast Track Designation for Immunopulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab Or Nivolumab
- Sbir) Program
- Approved Belbuca™ (Buprenorphine) (Talimogene Laherparepvec), A
- US FDA Expedited Programs and Expanded Access (Ke Liu)
- FAST TRACK REGISTRATION of COVID-19 VACCINES in BRAZIL Global Regulatory Partners, Inc
- FDA Briefing Document Amikacin Liposome Inhalation Suspension
- Off-Label Use of Prescription Drugs Should Be Regulated by the FDA
- The FDA Breakthrough-Drug Designation — Four Years of Experience
- LARTRUVO™ (Olaratumab) in Advanced Soft Tissue Sarcoma
- Coping with the Consequences of Accelerated Approval February 22, 2018
- Checkmate Pharmaceuticals Granted FDA Fast Track Designation For
- Medicines in Development ꟷ Antimicrobial Resistance (AMR)
- Risk Assessment and Risk Mitigation Review(S)
- 208624Orig1s000
- Expedited Development Programs and Emergency Access Mechanisms
- Report 2 of the Council on Science and Public Health (I-18) |
- Pulmonary and Critical Care Medication Update 2012
- Specialty Pipeline Update
- Expedited Programs for Regenerative Medicine Therapies for Serious Conditions
- Risk Assessment and Risk Mitigation Review(S)
- GAO-16-192 Highlights, DRUG SAFETY: FDA Expedites Many
- 2020 Annual Results Presentation
- Is Veklury (Remdesivir) Approved by the FDA to Treat COVID-19? A
- A Fast-Track Approval for New Medicines – Patient Safety at Risk?
- FDA Approves LARTRUVO™ (Olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma (STS)
- Expedited Programs for Serious Conditions – Drugs and Biologics
- Rxoutlook® Is Published by the Optumrx Clinical Services Department
- Fast Track Drug Development Programs — Designation, Development, and Application Review
- Medicines in Development ꟷ Infectious Diseases
- Accelerating Regulatory Approval for Drugs And